The Call for Opposition: Challenging the P2P and IOM Processes
In our second article on how to react to the publication of the draft P2P report, Gabby Klein provides her view of why she and a large group of advocates and patients are continuing their protest of the government’s ongoing control and manipulation of our disease via their processes...
Discuss the article on the Forums.

Watch Oct 3-4 to show the US gov't you care about ME/CFS

Discussion in 'Action Alerts and Advocacy' started by Hope123, Oct 1, 2012.

Thread Status:
Not open for further replies.
  1. SpecialK82

    SpecialK82 Senior Member

    Messages:
    963
    Likes:
    773
    USA
    It's back up now :)
     
  2. Dolphin

    Dolphin Senior Member

    Messages:
    7,271
    Likes:
    7,897
    Fair points.
     
  3. SpecialK82

    SpecialK82 Senior Member

    Messages:
    963
    Likes:
    773
    USA
    Go Mary!!
     
    alex3619 and Nielk like this.
  4. SpecialK82

    SpecialK82 Senior Member

    Messages:
    963
    Likes:
    773
    USA
    Dr. Joan Grobstein - Nice dressing down of committee
     
  5. alex3619

    alex3619 Senior Member

    Messages:
    8,730
    Likes:
    16,328
    Logan, Queensland, Australia
    Susan Meier - wow, I never knew the NIH was so fantastic! Look at what they do for everyone else. Lots of info on who they are. We need to know what they are doing. We need to know how things can improve. Some of what was reported on was peripheral research - like fatigue and sleep, pain, but they did fund XMRV research (Lipkin et. al.). The intro is mostly spin.

    One important thing is they made funding to the study showing increased association of lymphoma with CFS. They also have a bunch of plans that are still unfolding or intended.

    Ongoing research is broad. Last year $6.3M, this year 18% of applications were funded. Overall targeted and non-targeted funding is at 28% and 30%. The total amount is still dismal though.

    On discussing how to improve funding, by using an autism analogy, she commented on how it improved was increasing researchers and results, step by step, and action by advocates.

    Dr Fletcher (?) commented that funding applications and processes don't really suit multi-institute research.

    An issue that is identified, again, is that there are not enough ME or CFS research applications coming in.
     
    justinreilly likes this.
  6. alex3619

    alex3619 Senior Member

    Messages:
    8,730
    Likes:
    16,328
    Logan, Queensland, Australia
    The FDA spokesperson noted that they will be presenting information on how to create more effective advocacy.
     
    justinreilly likes this.
  7. alex3619

    alex3619 Senior Member

    Messages:
    8,730
    Likes:
    16,328
    Logan, Queensland, Australia
  8. Hope123

    Hope123 Senior Member

    Messages:
    1,216
    Likes:
    850
    Yeah, it was mostly "spin."

    Dr. Bateman isn't at the meeting. If it's the dark-haired physician, it's Susan Levine. If it's the older white-haired immunologist, that's Dr. Fletcher.
     
    justinreilly likes this.
  9. Valentijn

    Valentijn Activity Level: 3

    Messages:
    7,816
    Likes:
    13,172
    Amersfoort, Netherlands
    Is Sandra Kweder from the FDA going to say something relevant to ME soon, or is this just a random history lesson?

    I get the feeling it's going to lead into "it's our duty not to give you drugs".
     
    justinreilly likes this.
  10. Nielk

    Nielk

    Messages:
    6,000
    Likes:
    7,562
    Queens, NY
    I like her but, I'm not sure what she is saying? Are we to buy shares of the FDA?
    I'm guessing it's an introduction.
     
    justinreilly likes this.
  11. alex3619

    alex3619 Senior Member

    Messages:
    8,730
    Likes:
    16,328
    Logan, Queensland, Australia
    I was fairly sure I got the name wrong, thanks. It was Dr. Fletcher ... brain fog moment. Bye, Alex
     
  12. BEG

    BEG Senior Member

    Messages:
    943
    Likes:
    168
    Southeast US
    I put the history lesson on mute. Maybe she wants to talk away her time so there is no time left for comment. She is certainly verbose.
     
    justinreilly and Valentijn like this.
  13. alex3619

    alex3619 Senior Member

    Messages:
    8,730
    Likes:
    16,328
    Logan, Queensland, Australia
    FDA, Admiral Sandra Kweder: Controversy on definitions implies heterogeneity.

    We need homegenous cohorts, defined measures of outcomes, and good biomarkers. Biomarkers must correlate with function, they don't have to be diagnostic. The more heterogenous the cohort, the larger a clinical a trial is required.

    PS My comment: If this can be done, say goodbye psychobabble.
     
    justinreilly and Valentijn like this.
  14. BEG

    BEG Senior Member

    Messages:
    943
    Likes:
    168
    Southeast US
    Purple Dot Disease or Green Stripes, anyone?
     
  15. Hope123

    Hope123 Senior Member

    Messages:
    1,216
    Likes:
    850
    The other option to large clinical trials are smaller clinical trials that ONLY look at a specific subset -- e.g. people who fit both Canadian and Fukuda, say, or only people with viral onset, etc.
     
    SOC and alex3619 like this.
  16. alex3619

    alex3619 Senior Member

    Messages:
    8,730
    Likes:
    16,328
    Logan, Queensland, Australia
    What if you have purple dots on your green stripes? :eek:
     
    CJB and BEG like this.
  17. BEG

    BEG Senior Member

    Messages:
    943
    Likes:
    168
    Southeast US
    Well, I guess you've mixed your cohorts.:eek:
     
    SOC and CJB like this.
  18. Kina

    Kina Moderation Team Lead

    Messages:
    6,445
    Likes:
    6,029
    Ontario, Canada
Thread Status:
Not open for further replies.

See more popular forum discussions.

Share This Page